Evidence map›Paper›PMID 25245934›Full record

ArticleVaccine2014

Cancer immunotherapy using a potent immunodominant CTL epitope.

Liwen Song, Ming-Chieh Yang, Jayne Knoff, Zu-Yue Sun, T-C Wu, Chien-Fu Hung

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Liwen SongPharmacy School of Fudan University, Shanghai, China; Department of Obstetrics and Gynecology, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China; Departments of Pharmacology and Toxicology, Shanghai Institute of Planned Parenthood Research, Shanghai, China; Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, United States.
Ming-Chieh YangGeneral Surgery and Surgical Intensive Care, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Jayne KnoffDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, United States.
Zu-Yue SunDepartments of Pharmacology and Toxicology, Shanghai Institute of Planned Parenthood Research, Shanghai, China.
T-C WuDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, United States; Departments of Obstetrics and Gynecology, Johns Hopkins Medical Institutions, Baltimore, MD, United States; Departments of Molecular Microbiology and Immunology, Johns Hopkins Medical Institutions, Baltimore, MD, United States; Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, MD, United States.
Chien-Fu HungDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, United States; Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, MD, United States. Electronic address: chung2@jhmi.edu.
Johns Hopkins University · USTongji University · CN

Funding

Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporationP50CA098252 · NCI · JOHNS HOPKINS UNIVERSITY · PI Richard Bruce Roden · 2003 to 2026
$53.5M
ENHANCING HPV-16 E6-SPECIFIC ANTITUMOR IMMUNITYR01CA114425 · NCI · JOHNS HOPKINS UNIVERSITY · PI WU, TZYY-CHOOU · 2005 to 2016
$3.0M
Mechanisms of mucosal immune evasion in high grade cervical dysplasiaR01CA142691 · NCI · JOHNS HOPKINS UNIVERSITY · PI TRIMBLE, CORNELIA L · 2010 to 2014
$1.3M
NCI NIH HHS 2P50CA098252NCI NIH HHS 2R01CA114425-06NCI NIH HHS P50 CA098252NCI NIH HHS R01 CA114425NCI NIH HHS R01 CA142691NCI NIH HHS R01CA142691
6 · The paper itself

Abstract

Immunotherapy has emerged as a promising approach that can be used in conjunction with conventional chemotherapy and radiotherapy to further improve the survival rate of patients with advanced cancer. We have recently shown in previous studies that chemotherapy and radiation therapy can alter the tumor microenvironment and allow intratumoral vaccination to prime the adaptive immune system leading to the generation of antigen-specific cell-mediated immune responses. Here, we investigated whether intratumoral injection of a foreign immunodominant peptide (GP33) and the adjuvant CpG into tumors following cisplatin chemotherapy could lead to potent antitumor effects and antigen-specific cell-mediated immune responses. We observed that treatment with all three agents produced the most potent antitumor effects compared to pairwise combinations. Moreover, treatment with cisplatin, CpG and GP33 was able to control tumors at a distant site, indicating that our approach is able to induce cross-presentation of the tumor antigen. Treatment with cisplatin, CpG and GP33 also enhanced the generation of GP33-specific and E7-specific CD8+ T cells and decreased the number of MDSCs in tumor loci, a process found to be mediated by the Fas-FasL apoptosis pathway. The treatment regimen presented here represents a universal approach to cancer control.

Indexed as

ImmunotherapyAnimalsAntigens, NeoplasmCancer VaccinesCD8-Positive T-LymphocytesCisplatinCross-PrimingFemaleImmunity, CellularImmunodominant EpitopesMice, Inbred C57BLNeoplasms, ExperimentalOligodeoxyribonucleotidesPapillomavirus E7 ProteinsAntigens, NeoplasmCancer VaccinesCisplatinCPG-oligonucleotideImmunodominant EpitopesOligodeoxyribonucleotidesoncogene protein E7, Human papillomavirus type 16Papillomavirus E7 ProteinsCisplatinImmunodominant CTL epitopeImmunotherapy

Identifiers

PMID25245934
PMCPMC4194155
OpenAlexW2013321732

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.